Revlimid — Total Revenues
Bristol-Myers Squibb Revlimid — Total Revenues decreased by 31.4% to $575.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 59.3%, from $1.41B to $575.00M. Over 3 years (FY 2021 to FY 2024), Revlimid — Total Revenues shows a downward trend with a -23.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests strong market demand and successful patient adoption, while a decrease often signals the onset of generic competition or market saturation.
Detailed definition
This metric represents the total global net sales generated by the pharmaceutical product Revlimid. As a key oncology as...
Peer comparison
Comparable to revenue metrics for specific blockbuster drugs or flagship therapeutic assets at other large-cap pharmaceutical companies.
bmy_segment_revlimid_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.20B | $3.35B | $3.33B | $2.80B | $2.50B | $2.42B | $2.26B | $1.75B | $1.47B | $1.43B | $1.45B | $1.67B | $1.35B | $1.41B | $1.34B | $936.00M | $838.00M | $575.00M |
| QoQ Change | — | +4.5% | -0.6% | -16.0% | -10.6% | -3.2% | -6.6% | -22.6% | -16.1% | -2.7% | +1.5% | +15.1% | -18.9% | +4.4% | -5.2% | -30.1% | -10.5% | -31.4% |
| YoY Change | — | — | — | — | -21.9% | -27.7% | -32.1% | -37.4% | -41.3% | -41.0% | -35.8% | -4.6% | -7.8% | -1.2% | -7.7% | -43.9% | -38.1% | -59.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's revlimid — total revenues?
- Bristol-Myers Squibb (BMY) reported revlimid — total revenues of $575.00M in Q3 2025.
- How has Bristol-Myers Squibb's revlimid — total revenues changed year-over-year?
- Bristol-Myers Squibb's revlimid — total revenues decreased by 59.3% year-over-year, from $1.41B to $575.00M.
- What is the long-term trend for Bristol-Myers Squibb's revlimid — total revenues?
- Over 3 years (2021 to 2024), Bristol-Myers Squibb's revlimid — total revenues has grown at a -23.4% compound annual growth rate (CAGR), from $12.82B to $5.77B.
- What does revlimid — total revenues mean?
- The total revenue generated from the sales of the drug Revlimid.